Canada: Medical Diagnostics Patenting Faces Increased Challenges In Canada

Last Updated: August 17 2016
Article by Melanie Szweras and Carmela DeLuca

Intellectual property rights (IPR) are a key component for most if not all innovative activities.

For biotech companies in particular, one of the pillars for building value is a sound patent strategy and robust patent position for the key assets of the company.

Uncertainty in three areas can negatively impact innovation for IPR-driven sectors: uncertainty in the courts (i.e., litigation); uncertainty in patent office examination (i.e., whether patents will be granted and for what scope); and uncertainty in the laws protecting innovations in the innova­tors' home country compared with laws in other countries. Although there is little case law to judge in terms of uncertainty in the courts, recent changes in patent office examination policy with respect to medical diagnostics may have negative long term impacts on the innovative diagnostics in­dustry in Canada.

The Canadian Intellectual Property Of­fice (CIPO) released a Patent Notice to Ex­aminers in the summer of 2015 announcing changes to its examination of medical diagnostic methods - guidance that had been highly anticipated since CIPO had suspended its prosecution of diagnostic claims several years earlier.

Diagnostic innovations typically relate to the discovery of a correlation between genetic alterations or level of an analyte and a disease or disorder. The correlation discovery was viewed as able to generate the most valuable IP, and particularly so for companion diagnostics (after claims to the therapeutic composition or use thereof). Such IPRs related thereto have the ability to impact exclusivity for both the drug and the associated diagnostic.

The availability of IPRs directed to such a correlation discovery has been curtailed. Under the current Practice Notice, if the Examiner determines that the innovation is directed to improvements in measuring or detecting an analyte, it is more likely to be considered patentable subject matter whereas if the Examiner determines that the innovation is directed to the discovery of a correlation between an analyte and a diagnosis (without more), it is more likely to be considered unpatentable. CIPO's Practice Notice was introduced without significant consultation and without any clear basis in Canadian law. Although CIPO's interpretation of patentability does not have the force of law and can be challenged, the Notice has effectively cast more than a little doubt on the pat­ent eligibility of some precision medicine claims. Furthermore, CIPO acts as the gate-keeper to get an issued patent and under the current Practice Notice, innova­tors have no choice but to live within this system.

The changes to examination practice also put Canadian innovators in this sector at a disadvantage in their home country compared to, for example, their European counterparts.

The United States Patent and Trade­mark office over the last several years has been reducing the extent of protection available for diagnostics innovation. How­ever, such changes have been met with extensive scrutiny.

This shift in the CIPO examination pro­cedure seems to contradict the current Canadian Government focus on innova­tion, at least in relation to the life sciences industry. On January 20, 2016, Prime Minis­ter Trudeau provided a direct reference to the focus on innovation during his speech at the World Economic Forum in Davos, Switzerland. In his speech, Trudeau said "We need policies that encourage science, innovation and research. ... And we need governments willing to invest in making all that happen, while recognizing the dynamic innovation that happens in the private sector"1. This platform was backed up by the 2016 Canadian Federal Budget, which provided extensive funding com­mitments to scientific research, including funding for Genome Canada and other life science organizations as well as commit­ting to strengthen innovative networks and clusters2. However, the innovation agenda needs to be promoted in the government agencies that directly impact innovation in Canada, particularly innovation in the private sector. Otherwise, the govern­ment's focus on research will not translate innovation into the Canadian market. In other words, products and services stem­ming from these important correlation discoveries will not be brought to market by Canadian innovators and/or may not be readily available to Canadians.

Interestingly, there has been little objec­tion by the Canadian innovative diagnos­tics community to the clear diminishment of what is patentable for medical diagnos­tics. The reason behind this lack of reaction is unclear, but the changes have yet to have significant effect or to be appreciated fully (the second round of examination of diagnostic patent applications under these new guidelines is just emerging). One thing is clear: unless challenged or changed by the legislation, the current patent office practice will dramatically reduce the scope and type of claims and consequently the protection available for medical diagnos­tic innovations. In an era where precision medicine is positioned to transform the delivery of healthcare, reducing the incen­tives for innovation may negatively impact the Canadian diagnostics industry and place Canada at a disadvantage vis-à-vis other countries.


1 "The Canadian Opportunity", Davos, Swit­zerland, January 20, 2016, http://pm.gcca/eng/news/2016/01/20/canadian-opportunity-address-right-honourable-justin-trudeau-prime-minister-canada

2 Canadian Federal Budget 2016: Research & Innovation Investment Summary, Rob­ert Merson, Biotechnology Focus, March 23, 2016,

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Melanie Szweras
Carmela DeLuca
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.